

TITLE PAGE

Title: Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19

Subtitle: A Phase 2 Randomized Clinical Trial

AUTHORS:

Kara W. Chew, MD, MS, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA

Carlee Moser, PhD, Harvard T.H. Chan School of Public Health, Boston, MA

Eric S. Daar, MD, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA

David A. Wohl, MD, Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill NC, USA

Jonathan Z. Li, MD, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA

Robert Coombs, MD, PhD, Departments of Laboratory Medicine and Pathology; Department of Medicine, University of Washington, Seattle, WA, USA

Justin Ritz, MS, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Mark Giganti, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Arzhang Cyrus Javan, MD, MPH, DTM&H, National Institutes of Health, Bethesda, MD, USA

Yijia Li, MD, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA

Carlos Malvestutto, MD, MPH, Ohio State University Wexner Medical Center, Columbus, OH, USA

Paul Klekotka, MD, PhD, Eli Lilly and Company, San Diego, CA, USA

Karen Price, PhD, Eli Lilly and Company, Indianapolis, IN, USA

Ajay Nirula, MD, PhD, Eli Lilly and Company, San Diego, CA, USA

William Fischer, MD, Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill NC, USA

Veenu Bala, PhD, UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA

Ruy M. Ribeiro, PhD, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA

Alan S. Perelson, PhD, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA

Courtney V. Fletcher, PharmD, UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA

Joseph J. Eron, MD, Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill NC, USA

Judith S. Currier, MD, MSc, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA

*Michael D. Hughes, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, USA

*Davey M. Smith, MD, MAS, Department of Medicine, University of California, San Diego, La Jolla, CA, USA

For the ACTIV-2/A5401 Study Team

*Contributed equally

Corresponding Author: Kara W. Chew, MD, MS, UCLA Center for Clinical AIDS Research and Education, 911 Broxton Avenue, Suite 200, Los Angeles, CA 90024, phone (310) 825-0796, fax: (310) 477-7657, email: kchew@mednet.ucla.edu

1 **KEY POINTS**

2 **Question:** What is the safety and efficacy of bamlanivimab monoclonal antibody (mAb)
3 treatment for mild to moderate COVID-19?

4

5 **Findings:** In this randomized, placebo-controlled phase 2 trial of 317 non-hospitalized adults
6 with COVID-19, there was no relationship between symptoms or disease progression risk and
7 nasopharyngeal (NP) virus shedding. Bamlanivimab was safe and reduced NP SARS-CoV-2
8 RNA levels and inflammatory biomarker levels more than placebo, but did not shorten symptom
9 duration.

10

11 **Meaning:** Nasal virus shedding was not associated with symptoms or baseline risk factors for
12 severe COVID-19. Bamlanivimab, which has been associated with reduced hospitalizations in
13 high-risk individuals, demonstrated antiviral activity with early post-treatment NP sampling but
14 did not accelerate symptom improvement. The clinical utility of bamlanivimab for outcomes
15 other than hospitalizations and deaths, including longer-term outcomes, is uncertain.

16

17

18

19

20

21

22

23

24

25

26 **ABSTRACT**

27 **Importance:** The antiviral activity and efficacy of anti-SARS-CoV-2 monoclonal antibody (mAb)
28 therapies to accelerate recovery from COVID-19 is important to define.

29

30 **Objective:** To determine safety and efficacy of the mAb bamlanivimab to reduce
31 nasopharyngeal (NP) SARS-CoV-2 RNA levels and symptom duration.

32

33 **Design:** ACTIV-2/A5401 is a randomized, blinded, placebo-controlled platform trial. Two dose
34 cohorts were enrolled between August 19 and November 17, 2020 for phase 2 evaluation: in the
35 first, participants were randomized 1:1 to bamlanivimab 7000 mg versus placebo, and in the
36 second to bamlanivimab 700 mg versus placebo. Randomization was stratified by time from
37 symptom onset (\leq or >5 days) and risk of progression to severe COVID-19 (“higher” vs “lower”).

38

39 **Setting:** Multicenter trial conducted at U.S. sites.

40

41 **Participants:** Non-hospitalized adults ≥ 18 years of age with positive SARS-CoV-2 antigen or
42 nucleic acid test within 7 days, ≤ 10 days of COVID-19 symptoms, and with oxygen saturation
43 $\geq 92\%$ within 48 hours prior to study entry.

44

45 **Intervention:** Single infusion of bamlanivimab (7000 or 700 mg) or placebo.

46

47 **Main Outcomes and Measures:** Detection of NP SARS-CoV-2 RNA at days 3, 7, 14, 21, and
48 28, time to improvement of all of 13 targeted COVID-19 symptoms by daily self-assessment
49 through day 28, and grade 3 or higher treatment emergent adverse events (TEAEs) through day
50 28. Secondary measures included quantitative NP SARS-CoV-2 RNA, all-cause hospitalizations

51 and deaths (composite), area under the curve of symptom scores from day 0 through day 28,
52 plasma bamlanivimab concentrations, plasma and serum inflammatory biomarkers, and safety
53 through week 24.

54

55 **Results:** Ninety-four participants were enrolled to the 7000 mg cohort and 223 to the 700 mg
56 cohort and initiated study intervention. The proportion meeting protocol criteria for “higher” risk
57 for COVID-19 progression was 42% and 51% for the 7000 and 700 mg cohort, respectively.
58 Median time from symptom onset at study entry for both cohorts was 6 days. There was no
59 difference in the proportion with undetectable NP SARS-CoV-2 RNA at any post-treatment
60 timepoints (risk ratio compared to placebo, 0.82-1.05 for 7000 mg dose [overall $p=0.88$] and
61 0.81-1.21 for 700 mg dose [overall $p=0.49$]), time to symptom improvement (median of 21 vs
62 18.5 days, $p=0.97$, for 7000 mg bamlanivimab vs placebo and 24 vs 20.5 days, $p=0.08$, for 700
63 mg bamlanivimab vs placebo), or grade 3+ TEAEs with either dose compared to placebo.
64 Median NP SARS-CoV-2 RNA levels were lower at day 3 and C-reactive protein, ferritin, and
65 fibrinogen levels significantly reduced at days 7 and 14 for bamlanivimab 700 mg compared to
66 placebo, with similar trends observed for bamlanivimab 7000 mg. Viral decay modeling
67 supported more rapid decay with bamlanivimab compared to placebo.

68

69 **Conclusions and Relevance:** Treatment with bamlanivimab 7000 mg and 700 mg was safe
70 and compared to placebo led to more rapid reductions in NP SARS-CoV-2 RNA and
71 inflammatory biomarkers, but did not decrease time to symptom improvement. The clinical utility
72 of mAbs for outcomes other than hospitalizations and deaths is uncertain.

73

74 **Trial Registration:** ClinicalTrials.gov Identifier: NCT04518410

75

76 INTRODUCTION

77 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes
78 Coronavirus disease 2019 (COVID-19), continues to exert an enormous global public health and
79 economic toll, and in the U.S. case-fatality rates exceed estimates for the 1918 influenza
80 pandemic.¹ Anti-SARS-CoV-2 monoclonal antibody (mAb)-based therapies have shown
81 sufficient clinical efficacy to receive emergency authorization (EUA) by regulatory agencies for
82 the treatment of early COVID-19 in non-hospitalized persons.²⁻⁵

83

84 Bamlanivimab is a neutralizing immunoglobulin G (IgG)-1 mAb directed to the receptor binding
85 domain (RBD) of the spike (S) protein of SARS-CoV-2. On November 9, 2020, based on data
86 from the Blocking Viral Attachment and Cell Entry with SARS-CoV-2 Neutralizing Antibodies
87 (BLAZE-1) trial (NCT04427501)², the FDA issued an EUA for its use as a one-time 700 mg
88 intravenous (IV) infusion for the treatment for mild to moderate COVID-19 in non-hospitalized
89 adults with risk factors for progression to severe disease who were within 10 days of symptom
90 onset. Since then, the emergence of SARS-CoV-2 variants with decreased susceptibility *in vitro*
91 to bamlanivimab^{6,7} led to withdrawal of the EUA, although bamlanivimab in combination with
92 etesevimab continues to have an active EUA for the treatment of non-hospitalized adults.

93

94 With the rapid development of additional anti-SARS-CoV-2 mAbs, understanding the antiviral
95 activity and characterizing the clinical benefits of these agents remains a critical need. Here, we
96 describe the safety, virologic, and clinical outcomes of a placebo-controlled phase 2 evaluation
97 of bamlanivimab at two doses, 7000 mg and 700 mg, in non-hospitalized adults with COVID-19.

98

99 METHODS

100 Trial Design

101 The ACTIV-2/A5401 study is an ongoing multicenter phase 2/3 adaptive platform randomized
102 controlled trial for the evaluation of therapeutics for early COVID-19 in non-hospitalized adults
103 (see **Supplement 1** for the ACTIV-2/A5401 protocol). Phase 2 results for bamlanivimab
104 compared to placebo are reported here. All participants for this phase 2 analysis were enrolled
105 in the U.S., across 38 sites (listed in **Supplement 2**). The protocol was approved by a central
106 institutional review board (IRB), Advarra (Pro00045266), with additional local IRB review and
107 approval as required by participating sites. All participants provided written informed consent.

108

109 Participants

110 Adults 18 years of age or older with documented SARS-CoV-2 infection by an FDA-authorized
111 antigen or nucleic acid test from a sample collected within 7 days prior to anticipated study
112 entry, no more than 10 days of COVID-19 symptoms at time of anticipated study entry, ongoing
113 symptoms (not including loss of taste or smell) within 48 hours prior to study entry, resting
114 peripheral oxygen saturation levels $\geq 92\%$, and without the need for hospitalization were eligible.
115 Complete eligibility criteria are provided in the protocol in **Supplement 1**.

116

117 Randomization

118 Participants were randomly assigned by a web-based interactive response system in a 1:1 ratio
119 to receive either bamlanivimab or placebo. Randomization was stratified by time from symptom
120 onset (\leq or >5 days) and risk of progression to severe COVID-19 (“higher” vs “lower”). “Higher”
121 risk was defined in the protocol as meeting any of the following: age ≥ 55 years or having a
122 comorbidity (chronic lung disease or moderate to severe asthma, body mass index >35 kg/m²,
123 hypertension, cardiovascular disease, diabetes, or chronic kidney or liver disease).

124

125 Study Intervention

126 An initial dose of 7000 mg of bamlanivimab was chosen for study based on pharmacokinetic
127 (PK) and preliminary safety data. After phase 2 data on bamlanivimab 700 mg, 2800 mg, and
128 7000 mg from an outside trial did not conclusively demonstrate a dose-response effect of higher
129 doses on declines in nasopharyngeal (NP) SARS-CoV-2 RNA levels, the protocol was amended
130 to evaluate the 700 mg dose.⁸ Bamlanivimab or placebo (normal saline) was administered as a
131 single IV infusion over approximately 60 minutes.

132

133 Primary and Secondary Outcomes

134 The phase 2 study was designed to evaluate the safety of bamlanivimab and determine the
135 efficacy of bamlanivimab to reduce the duration of COVID-19 symptoms and SARS-CoV-2 RNA
136 shedding from NP swabs. NP swabs were collected on days 0 (day of study intervention, pre-
137 intervention), 3, 7, 14, 21, and 28. Participants completed a study diary each day from day 0 to
138 day 28, which included self-assessment of 13 targeted COVID-19 symptoms, scored by the
139 participant as absent, mild, moderate, or severe (see **Supplement 2** for symptom diary). A
140 numerical total symptom score was calculated for each day by summing scores for each
141 symptom, with absent scored as 0, mild as 1, moderate as 2, and severe as 3; therefore, the
142 range of total symptoms scores was 0 to 39.

143

144 Primary clinical outcome measures were: 1) development of a Grade 3 or higher treatment-
145 emergent adverse event (TEAE) through 28 days; 2) detection (detectable versus undetectable)
146 of SARS-CoV-2 RNA from NP swabs at days 3, 7, 14, 21, and 28; 3) duration of targeted
147 COVID-19-associated symptoms from day 0 (utilizing daily diary data), where duration was
148 defined as the number of days from day 0 to the last day on or before study day 28 when any
149 targeted symptoms that were self-assessed as moderate or severe at day 0 (before study
150 intervention) were still scored as moderate or severe (i.e., not mild or absent), or any targeted
151 symptoms scored as mild or absent at day 0 were still scored as mild or worse (i.e. not absent).

152 Participants with ongoing unimproved symptoms at day 28 were treated as having a symptom
153 duration of 28 days for analysis.

154

155 Secondary outcome measures included all-cause hospitalization and death, quantitative NP
156 SARS-CoV-2 RNA levels; area under the curve (AUC) of symptom scores from days 0-28; and
157 change in inflammatory markers from baseline through week 24; development of AEs of special
158 interest (AESIs, specifically Grade 1 or higher infusion-related reactions [IRRs] and Grade 1 or
159 higher allergic/hypersensitivity reactions), and serious adverse events (SAEs) through day 28
160 and through week 24; and progression of 1 or more COVID-19-associated symptoms to a worse
161 status than recorded in the study diary at entry. The full set of secondary and exploratory
162 outcome measures are provided in **Supplement 1** (protocol version 1.0).

163

164 Virology

165 NP and anterior nasal (AN) samples were collected using standardized swabs and collection
166 procedures. AN swabs were self-collected by participants daily days 0-14. Site-collected NP
167 swabs, AN swabs collected on site, and EDTA plasma samples were frozen and stored at -80°C
168 (-65°C to -95°C) on the day of collection. AN swabs collected remotely were stored at cool
169 temperatures (refrigerated or in a study-provided cooler with a combination of refrigerated and
170 frozen gel packs) and returned to the site and frozen at -80°C (-65°C to -95°C) within 7 days of
171 collection. Samples were shipped on dry ice to a central laboratory (University of Washington)
172 for quantitative SARS-CoV-2 RNA testing using the Abbott m2000sp/rt platform with a validated
173 internal standard.⁹ The collection, storage, processing, and assay methods have previously
174 been validated.⁹ The assay limit of detection (LoD) was 1.4 log₁₀ copies/mL, lower limit of
175 quantification (LLoQ) was 2 log₁₀ copies/mL, and upper limit of quantification (ULoQ) was 7 log₁₀

176 copies/mL. For samples with RNA levels >ULoQ, the assay was rerun with dilutions to obtain a
177 quantitative value.

178

179 The rates of decline of NP and AN virus after study entry were quantified in separate models
180 using Monolix 2020 (Lixoft, Antony, France). Methods for model fitting and selection are
181 described in **Supplement 2**.

182

183 Serum and plasma biomarkers

184 Inflammatory and coagulation markers including lactate dehydrogenase (LDH), C-reactive
185 protein (CRP), ferritin, D-dimer, prothrombin time (PT) and international normalized ratio (INR),
186 partial thromboplastin time (PTT), and fibrinogen were measured in real time by a central clinical
187 laboratory at days 0, 7, 14, 21, and 28 and weeks 12 and 24.

188

189 Pharmacokinetic (PK) analysis

190 Blood samples for quantitation of bamlanivimab serum concentrations were collected pre-dose
191 and at the following times after the end of infusion: 30 minutes, days 14 and 28 and weeks 12
192 and 24. PK parameters of interest were maximum concentration (C_{max}), area under the
193 concentration-time curve from time 0 to infinity (AUC_{0-∞}), elimination half-life and total body
194 clearance (CL), which were calculated based on the statistical moment theory using the
195 trapezoidal rule and linear regression (WinNonLin, Certara, Princeton, NJ, USA).

196

197 Power analysis and sample size calculation

198 The sample size of 110 participants randomized to each arm was selected to give high power to
199 identify an active agent based on the primary virologic outcome. At the time the study was
200 designed, there were no data in outpatients with COVID-19 to inform expected differences in

201 proportion undetectable for NP SARS-CoV-2 RNA over 28 days. We estimated that a 20%
202 absolute increase in the proportion undetectable would be clinically relevant, and 110
203 participants assigned to each arm would have 82.5 to 95.5% power dependent on the
204 proportion undetectable in the placebo arm, with a two-sided Type I error rate of 5%.

205

206 Statistical Analysis

207 The analysis population included all participants who initiated study intervention (bamlanivimab
208 or placebo). Four participants enrolled to the 7000 mg dose cohort received 700 mg
209 bamlanivimab or placebo and were included in the 700 mg analysis population (the
210 randomization to active agent or placebo remained valid). One participant enrolled in the 700
211 mg dose cohort received 7000 mg bamlanivimab and was included in the 7000 mg analysis
212 population.

213

214 The proportion of participants experiencing a grade 2 or higher and grade 3 or higher TEAE was
215 compared between arms using log-binomial regression and summarized with a risk ratio (RR),
216 corresponding 95% CI and p-value based on the Wald test. The proportion of participants with
217 undetectable SARS-CoV-2 RNA was compared between arms across study visits using Poisson
218 regression adjusted for baseline (day 0) \log_{10} transformed SARS-CoV-2 RNA level and
219 summarized with RR and 95% CI at each time, and Wald test across the multiple times.

220 Quantitative SARS-CoV-2 RNA levels were compared between arms using Wilcoxon rank-sum
221 tests, separately at each post-entry study visit, without adjustment for baseline value. For this
222 comparison, results below the LoD were imputed as the lowest rank and values above the LoD
223 but below the LLoQ were imputed as the second lowest rank. For summaries of quantitative
224 RNA levels, values below the LoD were imputed as $0.7 \log_{10}$ copies/ml (i.e., half the distance
225 from zero to the LoD), values above the LoD but below the LLoQ were imputed as $1.7 \log_{10}$
226 copies/ml (i.e., half the distance from the LoD to the LLoQ), and values above the ULoQ were

227 imputed as 8 log₁₀ copies/ml if a numerical value was not available. The two dose cohorts (700
228 and 7000 mg) were combined for analyses of baseline NP, AN, and plasma SARS-CoV-2 RNA
229 levels. Spearman correlations evaluated associations between total symptoms scores and NP
230 and AN RNA levels, Wilcoxon tests and chi-square tests were used to evaluate NP and AN
231 RNA levels and symptom scores between subgroups.

232

233 Participant-specific symptom durations and area under the curve (AUC) of total symptom score
234 from days 0-28 were compared between arms using a Wilcoxon rank sum test. Due to the small
235 number of hospitalization/death events, the proportion hospitalized/dead in the bamlanivimab
236 and placebo arms was summarized with descriptive statistics and compared between arms
237 using Fisher's exact test as a post-hoc analysis. Change from baseline in log-transformed
238 inflammatory and coagulation biomarker levels were compared between bamanivimab and
239 placebo arms using Wilcoxon tests.

240

241 No adjustment was made for the multiple comparisons across outcome measures. Statistical
242 analyses were conducted using SAS version 9.4 and R version 4.1.0. See **Supplement 1** for
243 complete Statistical Analysis Plan.

244

245 **RESULTS**

246 Characteristics of Participants and Retention in Follow-up

247 The analysis population included 94 participants in the bamlanivimab 7000 mg dose cohort (48
248 bamlanivimab, 46 placebo) enrolled between August 19 and November 15, 2020, and 223
249 participants in the bamlanivimab 700 mg dose cohort (111 bamlanivimab, 112 placebo) enrolled
250 between October 12 and November 17, 2020. Across bamlanivimab and placebo arms, 3
251 (3.2%) of the 7000 mg group, and 6 (2.6%) of the 700 mg group prematurely discontinued the
252 study prior to day 28 (**Figure 1**, Consort Flow Diagrams).

253

254 Participant characteristics were balanced across randomized arms in both the 7000 and 700 mg
255 groups (**Table 1**). Across all 317 participants included in analyses, 116 (37%) reported ≤ 5 days
256 of symptoms and 153 (48%) met the protocol definition of “higher” risk of progression to severe
257 COVID-19. Hypertension, diabetes, obesity, and age were the most common high-risk criteria
258 (**Supplementary Table 1**). The most frequently reported symptoms (reported by $>40\%$ of
259 participants) within 48 hours of study entry included cough, headache, body pain or muscle
260 pain/aches, fatigue, nasal obstruction or congestion, nasal discharge, and loss of taste or smell
261 (**Supplementary Table 2**); most symptoms were reported as mild or moderate.

262

263 Virological and Related Outcomes

264 Baseline NP and AN SARS-CoV-2 RNA levels (viral load) were highly correlated ($\rho=0.85$,
265 $p<0.001$) (**Figure 2A**), with AN viral load lower than NP viral load (median [interquartile range,
266 IQR] 4.5 [2.4, 6.3] and 5.7 [3.95, 6.8] \log_{10} copies/mL for AN and NP swabs, respectively).
267 Baseline NP and AN viral loads did not differ by risk category for COVID-19 progression
268 (median [IQR] NP viral load 5.4 [3.5, 8.4] vs 5.5 [3.7, 6.6] \log_{10} copies/mL, $p=0.8$) (**Figure 2B**),
269 but viral loads were higher among participants entering the study with ≤ 5 days vs >5 days of
270 symptoms (median NP viral load [IQR] 6.4 [5.2, 7.6] vs 4.8 [3.2, 6.1], $p<0.0001$) (**Figure 2C**)
271 and among plasma SARS-CoV-2 viremic vs aviremic participants (median NP viral load [IQR]
272 6.4 [5.3, 7.6] vs 5.3 [3.3, 6.5], $p<0.0001$) (**Figure 2D**). Twenty percent of participants had
273 detectable plasma SARS-CoV-2 RNA at baseline, without difference in proportion viremic by
274 risk category for COVID-19 progression (**Figure 2E**). Total symptom score was higher among
275 viremic vs aviremic participants at baseline (**Figure 2F**); symptom score did not correlate with
276 NP or AN viral load (**Figure 2E**).

277

278 Baseline NP SARS-CoV-2 RNA levels were similar at study entry between bamlanivimab vs
279 placebo arms in each bamlanivimab dose cohort (**Supplementary Table 3**). The proportion of
280 participants with undetectable NP SARS-CoV-2 RNA (primary virologic outcome) increased
281 over time and did not differ between bamlanivimab or placebo arms for either dose cohort
282 (**Figure 3 and Supplementary Table 3**). At day 3, the median NP SARS-CoV-2 RNA level was
283 significantly lower among bamlanivimab 700 mg recipients compared to placebo (2.9 vs 3.9
284 \log_{10} copies/mL, $p=0.002$), and a similar trend was observed for bamlanivimab 7000 mg
285 compared to placebo (2.2 vs 3.4 \log_{10} copies/mL, $p=0.07$) (**Supplementary Table 3**). No
286 differences in SARS-CoV-2 RNA levels between bamlanivimab and placebo groups were
287 observed at any of the later visits (**Figure 3 and Supplementary Table 3**). Additionally, the
288 AUC for SARS-CoV-2 RNA from day 0 through day 28 was smaller for both bamlanivimab 700
289 mg and 7000 mg compared to placebo, but neither difference met statistical significance
290 (**Supplementary Table 3**).

291
292 The viral load decay from NP and AN swab data was fitted for those participants for whom there
293 was enough data (**Supplementary Table 4A**). Decay rates were similar for each dose cohort
294 (**Supplementary Table 4B**); thus, the 700 and 7000 mg dose cohorts were combined and fitted
295 together, with separate analyses for NP and AN data. Population parameter estimates for the
296 viral load decay in NP and AN swabs are provided in **Supplementary Table 4C**. The best
297 model for AN data had a single exponential decay, and for the NP data, a biexponential decay.
298 The first phase of viral decay was fast (AN: $t_{1/2}=7.8$ and 6.5 hours and NP: $t_{1/2}= 10.3$ and 7.2
299 hours for placebo and bamlanivimab-treated participants, respectively), while the second phase
300 was slightly slower with $t_{1/2}=15.1$ hours (in NP), with no difference in the second phase decay
301 rate between placebo and bamlanivimab-treated participants. In both AN and NP models, the
302 first phase of decay was significantly faster ($p=0.0049$ and $p=0.0002$, respectively) for
303 bamlanivimab treatment compared to placebo.

304

305 Symptoms and Other Clinical Outcomes

306 Overall, time to symptom improvement (primary symptom outcome) was long and did not differ
307 significantly between bamlanivimab vs placebo arms for either dose cohort (median of 21 and
308 18.5 days for bamlanivimab 7000 mg vs placebo, $p=0.97$ and 24 vs 20.5 days for bamlanivimab
309 700 mg vs placebo, $p=0.08$) (**Table 2**). AUC of the total symptom score reported daily days 0-28
310 in the study diary also did not differ significantly between bamlanivimab vs placebo arms for
311 either dose cohort (**Table 2**).

312

313 CRP, ferritin, and fibrinogen levels declined more rapidly (greater fold change from baseline) in
314 bamlanivimab 700 mg compared to placebo recipients at days 7 and 14 (as well as week 24 for
315 CRP) (**Supplementary Figures 3 and 4**). Greater fold-change reductions in prothrombin time
316 (PT) were also observed at Days 14, 21, and Week 12 with bamlanivimab 700 mg. Similar
317 trends were observed at some time points for bamlanivimab 7000 mg vs placebo
318 (**Supplementary Figure 4**). No differences between bamlanivimab vs placebo arms were
319 observed for fold change from baseline for LDH or activated PTT through day 28
320 (**Supplementary Figures 3 and 4**).

321

322 Through study day 28, there were 6 hospitalizations in the 7000 mg group, 2 (4.2%) on
323 bamlanivimab and 4 (8.7%) on placebo, and 8 hospitalizations in the 700 mg group, 4 (3.6%) on
324 bamlanivimab and 4 (3.6%) on placebo. No deaths were observed through week 24.

325 Hospitalizations and deaths through week 24 are summarized in **Supplementary Table 5**.

326

327 Safety

328 TEAEs through study day 28 are summarized in **Table 3** and TEAEs through week 24 in
329 **Supplementary Table 6**. Grade 2 or higher and grade 3 or higher TEAEs were generally more
330 frequently reported in bamlanivimab 700 and 7000 mg recipients than in placebo recipients, but
331 the proportion with grade 3 or higher TEAEs (the primary safety outcome) did not differ
332 significantly between bamlanivimab vs placebo arms for either dose and the vast majority of
333 TEAEs were not felt to be related to study intervention. AESIs were infrequent and led to
334 premature treatment discontinuation in only one participant assigned bamlanivimab 7000 mg,
335 who did not complete the infusion due to a grade 3 IRR. SAEs through day 28 occurred in 2
336 (4.2%) and 4 (8.7%) of bamlanivimab 7000 mg and placebo recipients, respectively, and in 4
337 (3.6%) and 3 (2.7%) of bamlanivimab 700 mg and placebo recipients, respectively (**Table 3**).
338 Detailed summaries of grade 2 and higher and grade 3 and higher TEAEs through day 28 by
339 dose cohort and treatment arm are provided in **Supplementary Tables 7 and 8**.

340

341 Pharmacokinetics

342 PK data were obtained on a total of 108 participants (71 who received 700 mg and 37 who
343 received 7000 mg), as summarized in **Supplementary Table 9**. Mean C_{max} values for the 700
344 mg and 7000 mg doses were 206 and 1867 µg/mL, respectively, and mean day 28
345 concentrations were 29 and 236 µg/mL, respectively. There was evidence for approximate dose
346 proportionality, with geometric mean ratios for C_{max} and AUC_{0-∞} of 8.3 and 8.5, respectively; the
347 geometric mean ratio for total body clearance (CL) was 1.2. Interpatient variability was modest
348 with coefficients of variation (CV) on CL of 40.5% at the 700 mg dose and 88.9% at the 7000
349 mg dose. Of bamlanivimab 700 mg recipients, 70/71 (98.6%) had day 28 concentrations above
350 the estimated 90% inhibitory concentration (IC₉₀) of bamlanivimab for SARS-CoV-neutralization
351 of 4.2 µg/mL;¹⁰ one participant had bamlanivimab concentrations below the limit of quantitation
352 at day 28.

353

354 **DISCUSSION**

355 We present results of a phase 2 evaluation of the safety and efficacy of single dose
356 bamlanivimab 700 mg and partially enrolled phase 2 evaluation of single dose bamlanivimab
357 7000 mg given by IV infusion for the treatment of non-hospitalized adults with COVID-19. For
358 both bamlanivimab dose cohorts, in which participants received study intervention a median of 6
359 days from symptom onset, the intervention was safe, but no improvement was observed with
360 bamlanivimab in the primary outcomes of proportion of participants with undetectable SARS-
361 CoV-2 RNA from NP swabs or time to improvement of COVID-19-related symptoms. However,
362 quantitative SARS-CoV-2 RNA levels from NP swabs were significantly lower among
363 bamlanivimab-treated participants at a dose of 700 mg compared to placebo at day 3 of study,
364 with a similar trend in the smaller 7000 mg dose cohort. Viral decay rates were modeled to be
365 significantly faster for bamlanivimab compared to placebo. These observations are consistent
366 with improvements in the semi-quantitative SARS-CoV-2 RNA measures by cycle threshold (Ct)
367 observed with bamlanivimab in the BLAZE-1 trial. Of note, the SARS-CoV-2 RNA assay used in
368 ACTIV-2/A5401 was fully quantitative and timing of treatment initiation after symptom onset was
369 later than in BLAZE-1 (median of 6 vs 4 days of symptoms).²

370

371 Consistent with the reductions in NP SARS-CoV-2 RNA levels, we also found biological
372 evidence of activity of bamlanivimab against COVID-19 progression, with greater reductions in
373 inflammatory biomarker levels (CRP, ferritin, and fibrinogen) with bamlanivimab compared to
374 placebo. While no impact of bamlanivimab therapy on symptom duration was found in our study,
375 we note that symptom-based outcome measures for assessing treatment response have not yet
376 been validated and persistence or brief recurrence of mild symptoms may have made our
377 primary symptom outcome definition overly sensitive to symptoms that may not have been
378 clinically meaningful. Across outpatient COVID-19 therapeutic studies, definitions of symptom
379 improvement or resolution, symptom diaries, severity scoring scales, analytical approaches, and

380 included symptoms have differed. The BLAZE-1 study first examined change from baseline in
381 symptom scores and found modest early reductions in symptom scores with bamlanivimab
382 compared to placebo.² Subsequent analyses of the combination mAbs bamlanivimab and
383 etesevimab examined different definitions of symptom resolution or improvement, and found a 1
384 day reduction (8 vs 9 days) in median time to sustained resolution of symptoms, where
385 sustained resolution of symptoms was defined by 2 consecutive days of absent symptoms (6
386 targeted), allowing for ongoing mild cough and fatigue.¹¹

387

388 The combination mAbs casirivimab and imdevimab reduced symptom duration by 4 days (from
389 14 to 10) utilizing a different symptom resolution definition of time to first day the participant
390 scored 19 symptoms absent, allowing ongoing “mild/moderate” cough, fatigue, and headache,
391 and restricting to participants with a minimum symptom score >3.¹² One obvious impact of the
392 different definitions of symptom resolution is on the duration of symptoms from study entry –
393 shorter durations were reported in the BLAZE-1 and REGEN-COV studies than in our study
394 (median durations of >20 days). Based on clinical observations that COVID-19 symptoms may
395 wax and wane day-to-day, we sought to minimize the possibility of recurrent or relapsing
396 symptoms in defining our population with improved symptoms, resulting in long durations of
397 symptoms. An additional challenge is distinguishing between symptoms that are specific to
398 COVID-19 or due to comorbidities, given many viral illness symptoms are non-specific. The
399 potential for mAbs to modify symptom duration and accelerate symptom resolution may also
400 depend on timing of mAb therapy during the COVID-19 disease course – where later
401 administration (as late as 10 days after symptom onset, as in our study and consistent with
402 current mAb EUA guidance) may have less impact, although this is unknown. Validation of
403 COVID-19 symptom diary content and outcome measures are ongoing, by our group and
404 others.

405

406 Additionally, the impact of early antiviral therapy and mAbs on long-term post-acute sequelae of
407 SARS-CoV-2 infection (PASC) is unknown. Defining and measuring PASC presents similar, if
408 not greater challenges to those of defining acute COVID-19 symptom resolution/improvement.
409 The reductions in inflammatory biomarkers with bamlanivimab, including as late as 24 weeks
410 after treatment, suggest some promise for early antiviral therapy to mitigate or prevent the
411 development of PASC, or some PASC presentations. Studies to quantify the potential benefit of
412 early antiviral therapy on late COVID-19 sequelae are also ongoing, by our group and others.
413

414 The ACTIV-2/A5401 outcome measures were designed early in the COVID-19 pandemic, and
415 our understanding of the SARS-CoV-2 viral kinetics on NP and AN sampling continues to
416 evolve. At the time the study was designed, the dynamics of RNA shedding from the
417 nasopharynx and anterior nares in people with mild-moderate symptoms and correlates of NP
418 and AN viral levels were not well described. Our study clearly demonstrates that while viral
419 shedding in these compartments was not greater in participants at higher risk of disease
420 progression or correlated with self-reported symptom scores, it was associated with shorter
421 duration of symptoms and NP (and AN, data not shown) RNA shedding declines rapidly in most
422 individuals, even in the absence of treatment. NP RNA shedding as a measure of antiviral
423 activity is likely to be most informative early after symptom onset and with very early sampling
424 following treatment.

425
426 Consistent with this, greater reductions in NP SARS-CoV-2 RNA compared to placebo have
427 been observed for multiple anti-SARS-CoV-2 neutralizing mAbs in parallel with reductions in
428 COVID-19-related hospitalizations and deaths, in studies where the mAbs were administered
429 early after symptom onset (median of 3-4 days), and earlier than in our study.^{2-4,11} Whether
430 antiviral/mAb therapy has a clinical benefit after a longer duration of symptoms is a separate
431 question from detecting antiviral activity (i.e. the value of change in NP RNA levels as a

432 surrogate for clinical outcomes is likely limited to a short window during early infection, when
433 RNA levels are high, and may not be similarly predictive or correlated later in the disease
434 course, nor reflective of antiviral activity). Indeed, our group has demonstrated the clinical
435 benefit of anti-SARS-CoV-2 mAbs (the combination of BR11-196 and BR11-198 administered IV)
436 given as late as 10 days after symptom onset, with similar reductions in hospitalizations and
437 deaths when given >5 days vs within 5 days from symptom onset;¹³ analyses of NP RNA
438 shedding and hospitalization/death rates by symptom duration at time of treatment in this phase
439 2/3 trial within the ACTIV-2/A5401 platform will be informative.

440

441 Our study also demonstrates that NP and AN RNA shedding is greater among non-hospitalized
442 persons with SARS-CoV-2 viremia compared to those without detectable viremia, and symptom
443 scores also tend to be higher among viremic compared to aviremic participants. Given the small
444 number of hospitalizations, we could not determine if nasal shedding, viremia, or changes with
445 treatment were associated with this outcome or COVID-19 severity, as has been observed in
446 hospitalized persons.^{14,15}

447

448 In this study, we also expand on the reported PK of bamlanivimab and found the characteristics
449 in 108 non-hospitalized persons were comparable with those reported in the first-in-human
450 study in hospitalized patients for both the 700 and 7000 mg doses.¹⁶ Absolute dose proportional
451 PK were not observed, explained by the faster total body clearance with 7000 mg than 700 mg.
452 The 700 mg dose (the dose that was granted an EUA) achieved sustained serum
453 concentrations above the predicted IC₉₀ for SARS-CoV-2 neutralization in nearly all participants
454 with available PK data, supporting the selection of this dose for clinical use. However,
455 bamlanivimab concentrations in target tissues such as the respiratory tract have not been
456 measured in humans and whether this same pharmacodynamic relationship exists in tissues is
457 not known.

458

459 These phase 2 trial results affirm the overall safety and antiviral activity of bamlanivimab
460 reported previously and suggest a benefit on systemic inflammation. While the safety and
461 efficacy of anti-SARS-CoV-2 mAbs for the prevention of hospitalizations and deaths in persons
462 at high risk of progressive disease have been established, further evaluation is needed to define
463 the benefit of early treatment with mAbs on symptom outcomes in persons at lower risk for
464 severe COVID-19 and on longer-term outcomes, such as PASC.

465 **Acknowledgements**

466 We thank the AIDS Clinical Trials Group, including Lara Hosey and Jhoanna Roa; the National
467 Institute of Allergy and Infectious Diseases (NIAID) / Division of AIDS (DAIDS), including Peter
468 Kim; the U.S. Government Response to COVID-19, including Bill Erhardt; the Foundation for the
469 National Institutes of Health and the Accelerating COVID-19 Therapeutic Interventions and
470 Vaccines (ACTIV) partnership, including Stacey Adams; and PPD.

471

472 We also thank the members of the ACTIV-2/A5401 data and safety monitoring board —
473 Graeme A. Meintjes, PhD, MBChB (Chair), Barbara E. Murray, MD, Stuart Campbell Ray, MD,
474 Valeria Cavalcanti Rolla, MD, PhD, Haroon Saloojee, MB.BCh, FCPaed, MSc, Anastasios A.
475 Tsiatis, PhD, Paul A. Volberding, MD, Jonathan Kimmelman, PhD, David Glidden, PhD, and
476 Sally Hunsberger, PhD (Executive Secretary).

477

478 **Funding**

479 This work was supported by the National Institute of Allergy and Infectious Diseases of the
480 National Institutes of Health under Award Number 3UM1AI068636-14S2, UM1 AI068634, UM1
481 AI068636 and UM1 AI106701. The content is solely the responsibility of the authors and does
482 not necessarily represent the official views of the National Institutes of Health. Portions of this
483 work were performed at Los Alamos National Laboratory under the auspices of the US Dept. of
484 Energy under contract 89233218CNA000001 and supported by NIH grants R01-AI028433, R01-
485 OD011095 (ASP), and Los Alamos National Laboratory LDRD 20200743ER, 20200695ER, and
486 20210730ER. Study medication was donated by Eli Lilly and Company.

487

488 **Conflicts of Interest**

489 KWC has received research funding to the institution from Merck Sharp & Dohme. ESD
490 receives consulting fees from Gilead Sciences and Merck and research support through the
491 institution from Gilead Sciences and ViiV. DAW has received funding to the institution to support
492 research and honoraria for advisory boards and consulting from Gilead Sciences. JZL has
493 consulted for Abbvie. ASP has consulted for Amphylix Pharmaceuticals. C. Malvestutto has
494 received research funding to the institution from Eli Lilly. PK, KP, and AN are employees and
495 shareholders of Eli Lilly. WF has received research funding from Ridgeback
496 Biopharmaceuticals, served on adjudication committees for Janssen, Syneos, and consulted for
497 Roche and Merck. JJE is an ad hoc consultant to GSK/VIR, data monitoring committee (DMC)
498 chair for Adagio Phase III studies. DMS has consulted for the following companies Fluxergy,
499 Kiadis, Linear Therapies, Matrix BioMed, Arena Pharmaceuticals, VxBiosciences, Model
500 Medicines, Bayer Pharmaceuticals, Signant Health and Brio Clinical.

501

502 **Data Sharing Statement:** The authors confirm that all data underlying the findings are fully
503 available. Due to ethical restrictions, study data are available upon request from
504 sdac.data@sdac.harvard.edu with the written agreement of the AIDS Clinical Trials Group and
505 the manufacturer of the investigational product.


506

507 **REFERENCES**

- 508 1. Taubenberger JK, Kash JC, Morens DM. The 1918 influenza pandemic: 100 years of
509 questions answered and unanswered. *Sci Transl Med*. Jul 24
510 2019;11(502)doi:10.1126/scitranslmed.aau5485
- 511 2. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in
512 Outpatients with Covid-19. *N Engl J Med*. Jan 21 2021;384(3):229-237.
513 doi:10.1056/NEJMoa2029849
- 514 3. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in
515 Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A
516 Randomized Clinical Trial. *JAMA*. Feb 16 2021;325(7):632-644. doi:10.1001/jama.2021.0202
- 517 4. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody
518 Cocktail, in Outpatients with Covid-19. *N Engl J Med*. Jan 21 2021;384(3):238-251.
519 doi:10.1056/NEJMoa2035002
- 520 5. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-
521 CoV-2 Neutralizing Antibody Sotrovimab. *N Engl J Med*. Oct 27
522 2021;doi:10.1056/NEJMoa2107934
- 523 6. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and
524 B.1.1.7. *Nature*. May 2021;593(7857):130-135. doi:10.1038/s41586-021-03398-2
- 525 7. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta
526 to antibody neutralization. *Nature*. Aug 2021;596(7871):276-280. doi:10.1038/s41586-021-
527 03777-9
- 528 8. Eli Lilly and Company, News Release. September 16, 2020,
529 [https://investor.lilly.com/news-releases/news-release-details/lilly-announces-proof-concept-data-](https://investor.lilly.com/news-releases/news-release-details/lilly-announces-proof-concept-data-neutralizing-antibody-ly)
530 [neutralizing-antibody-ly](https://investor.lilly.com/news-releases/news-release-details/lilly-announces-proof-concept-data-neutralizing-antibody-ly)


- 531 9. Berg MG, Zhen W, Lucic D, et al. Development of the RealTime SARS-CoV-2
532 quantitative Laboratory Developed Test and correlation with viral culture as a measure of
533 infectivity. *J Clin Virol*. Oct 2021;143:104945. doi:10.1016/j.jcv.2021.104945
- 534 10. Chigutsa E, O'Brien L, Ferguson-Sells L, Long A, Chien J. Population Pharmacokinetics
535 and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in
536 Patients With Mild to Moderate COVID-19 Infection. *Clin Pharmacol Ther*. Nov
537 2021;110(5):1302-1310. doi:10.1002/cpt.2420
- 538 11. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate
539 Covid-19. *N Engl J Med*. Jul 14 2021;doi:10.1056/NEJMoa2102685
- 540 12. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination
541 and Outcomes in Outpatients with Covid-19. *N Engl J Med*. Sep 29
542 2021;doi:10.1056/NEJMoa2108163
- 543 13. Evering T GM, Chew K, Hughes M, Moser C, Wohl D, Currier J, Eron J, Javan A,
544 Margolis DA, Zhu Q, D'Andrea U, Hoover K, Mocherla BR, Fletcher C, Li J, Smith D, Daar E.
545 Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb)
546 BR11-196 and BR11-198 in Non-Hospitalized COVID-19 Patients. presented at: IDWeek;
547 September 30, 2021 Virtual Conference. Session (55) COVID-19 Treatment & Prophylaxis.
- 548 14. Jacobs JL, Bain W, Naqvi A, et al. SARS-CoV-2 Viremia is Associated with COVID-19
549 Severity and Predicts Clinical Outcomes. *Clin Infect Dis*. Aug 10 2021;doi:10.1093/cid/ciab686
- 550 15. Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with
551 increased disease severity and mortality. *Nat Commun*. Oct 30 2020;11(1):5493.
552 doi:10.1038/s41467-020-19057-5
- 553 16. Chen P, Datta G, Grace Li Y, et al. First-in-Human Study of Bamlanivimab in a
554 Randomized Trial of Hospitalized Patients With COVID-19. *Clin Pharmacol Ther*. Dec
555 2021;110(6):1467-1477. doi:10.1002/cpt.2405

Figure 1A. CONSORT Flow Diagram, Bamlanivimab 7000 Dose Group



^aIncludes 1 participant assigned bamlanivimab 700 mg

Figure 1B. CONSORT Flow Diagram, Bamlanivimab 700 Dose Group



^aIncludes 2 participants assigned bamlanivimab 7000 mg; ^bIncludes 2 participants assigned placebo 7000 mg

Figure 2. Associations between baseline virology and symptom scores and comparisons by subgroups, combining bamlanivimab 700 and 7000 mg dose cohorts. (A) Baseline nasopharyngeal (NP) and anterior nasal (AN) SARS-CoV-2 RNA levels (viral loads) were highly correlated. The diagonal line indicates line of equality. NP and AN viral loads did not differ by protocol-defined risk category (“higher” vs “lower”) for COVID-19 progression (B), but were significantly higher among participants entering the study with fewer days of symptoms (≤ 5 vs > 5 days) (C) and among viremic vs aviremic participants (D). The proportion with SARS-CoV-2 viremia at study entry was the same for participants at higher vs lower risk for COVID-19 progression (E). Total symptom scores reported at study entry in the participant diary were higher among viremic participants (F). Symptoms scores did not correlate with NP or AN viral loads (G). In Figures 2B-2D and 2F, Tukey boxplots were used to demonstrate the distribution of viral loads or symptom score. Wilcoxon rank sum test was used to compare values from different groups.




Figure 3. Nasopharyngeal (NP) SARS-CoV-2 RNA levels (viral loads) by dose cohort, treatment arm and visit. NP viral loads declined in all participants, with median NP viral loads lower at day 3 for bamlanivimab 700 mg (n=111) vs placebo (n=112) (2.9 vs 3.9 log₁₀ copies/mL, p=0.002) (A), without a difference in proportion undetectable at any time points (B). Similar findings were seen, though differences in median viral load at day 3 were not statistically significant for the smaller 7000 mg dose cohort (n=48 bamlanivimab vs n=46 placebo, 2.2 vs 3.4 log₁₀ copies/mL, p=0.07) (C and D). The lower limit of detection was 1.4 log₁₀ copies/mL.




Table 1. Baseline participant characteristics by dose group and treatment arm.

Characteristic	7000 mg dose cohort			700 mg dose cohort		
	Bamlanivimab (N=48)	Placebo (N=46)	Total (N=94)	Bamlanivimab (N=111)	Placebo (N=112)	Total (N=223)
Age, years, median (IQR)	45.5 (33.5, 57.5)	42.0 (28.0, 54.0)	44.5 (30.0, 56.0)	46.0 (35.0, 54.0)	48.5 (36.0, 55.0)	47.0 (35.0, 55.0)
Sex, n (%)						
Female	26 (54.2)	23 (50.0)	49 (52.1)	57 (51.4)	56 (50.0)	113 (50.7)
Male	22 (45.8)	23 (50.0)	45 (47.9)	54 (48.6)	56 (50.0)	110 (49.3)
Race, n (%)						
White	41 (85.4)	37 (80.4)	78 (83.0)	92 (82.9)	92 (82.9)	184 (82.9)
Black	3 (6.3)	2 (4.3)	5 (5.3)	13 (11.7)	10 (9.0)	23 (10.4)
Asian	0 (0)	5 (10.9)	5 (5.3)	2 (1.8)	4 (3.6)	6 (2.7)
Other ^a	4 (8.3)	2 (4.3)	6 (6.4)	4 (3.6)	5 (4.5)	9 (4.0)
Missing	0	0	0	0	1	1
Ethnicity, n (%)						
Hispanic/Latino	15 (31.3)	17 (37.8)	32 (34.4)	18 (16.2)	31 (28.2)	49 (22.2)
Not Hispanic/Latino	33 (68.8)	28 (62.2)	61 (65.6)	93 (83.8)	79 (71.8)	172 (77.8)
Missing	0	1	1	0	2	2
Days from symptom onset at study entry (IQR)	6.0 (4.0, 8.0)	5.5 (4.0, 7.0)	6.0 (4.0, 7.0)	6.0 (4.0, 8.0)	6.0 (4.0, 7.0)	6.0 (4.0, 8.0)
≤5 days, n (%)	17 (35.4)	17 (37.0)	34 (36.2)	41 (36.0)	41 (36.6)	82 (36.8)
>5 days, n (%)	31 (64.6)	29 (63.0)	60 (63.8)	70 (63.1)	71 (63.4)	141 (63.4)
Risk of COVID-19 progression, n (%)						
Higher risk	20 (41.7)	19 (41.3)	39 (41.5)	58 (52.3)	56 (50.0)	114 (51.1)
Lower risk	28 (58.3)	27 (58.7)	55 (58.5)	53 (47.7)	56 (50.0)	109 (48.9)
BMI (kg/m ²), median (IQR)	28.2 (24.9, 31.8)	28.8 (25.0, 31.3)	28.5 (25.0, 31.8)	28.4 (25.1, 33.9)	27.1 (23.8, 32.1)	27.8 (24.5, 32.9)
Missing	6	7	13	16	15	31

^aOther includes Asian, American Indian or Alaskan, multiple races, and other
IQR = interquartile range; BMI = body mass index

Table 2. Symptom outcomes by bamlanivimab dose cohort and treatment arm

	7000 mg dose cohort			700 mg dose cohort		
	Bamlanivimab (N=48)	Placebo (N=46)	p-value	Bamlanivimab (N=111)	Placebo (N=112)	p-value
Time to symptom improvement from study entry (primary symptom outcome), median (IQR), days	21.0 (7.0, 28.0)	18.5 (7.0, 28.0)	0.97 ^a	24.0 (14.0, 28.0)	20.5 (9.0, 28.0)	0.08 ^a
Proportion of participants with at least 1 symptom reported as more severe than at study entry in study diary, n (%)	42 (87.5)	40 (87.0)	0.94 ^b	102 (91.9)	105 (93.8)	0.59 ^b
Symptom severity ranking (AUC of total symptom score days 0-28), median (IQR)	1.38 (0.93, 3.09)	1.88 (1.09, 3.05)	0.14 ^a	2.34 (1.30, 3.93)	2.13 (1.06, 4.08)	0.65 ^a

IQR = interquartile range, ^aWilcoxon test, ^bchi-square test

Table 3. Adverse events (AEs) through day 28

Event	7000 mg dose group			700 mg dose cohort		
	Bamlanivimab (n=48)	Placebo (n=46)	Risk Ratio (bamlanivimab 7000 mg vs placebo) (95% CI), p-value ^a	Bamlanivimab (n=111)	Placebo (n=112)	Risk Ratio (bamlanivimab 700 mg vs placebo) (95% CI), p-value ^a
Grade 3 or higher TEAEs through day 28 (primary safety outcome), number of participants (%)	6 (12.5)	6 (13.0)	0.96 (0.33, 2.76), p=0.94	10 (9.0)	6 (5.4)	1.68 (0.63, 4.47), p=0.30
Grade 2 or higher TEAEs through day 28, number of participants (%)	18 (37.5)	14 (30.4)	1.23 (0.697, 2.2), p=0.47	41 (36.9)	25 (22.3)	1.65 (1.08, 2.52), p=0.02
AEs leading to premature treatment discontinuation, number of participants (%)	1 (2.1)	0	--	0	0	--
AESIs through day 28, number of participants (%)	1 (2.1)	2 (4.3)	--	1 (0.9)	3 (2.7)	--
Infusion-related reaction	1 (2.1)	1 (2.2)	--	1 (0.9)	1 (0.9)	--
Hypersensitivity reaction	0	1 (2.2)	--	0	2 (1.8)	--
Serious adverse events (SAEs) through day 28, number of participants (%)	2 (4.2)	4 (8.7)	--	4 (3.6)	3 (2.7)	--

TEAE = treatment emergent adverse event; AESI = adverse event of special interest; ^aWald test